In the News

By Katie Taranto; Published March 10, 2025 at 3:45PM A Dominion Hills woman diagnosed with early-onset Parkinson’s disease received national recognition last month for her advocacy work. Allison Signorelli was honored with the Citizen Scientist Cultivator Award for participating in various research trials after being diagnosed with the disease in 2022 at age 47. Signorelli has spent the […]

 International non-profit expands research network to Syracuse to improvecommunity access to research opportunities Washington D.C., Mar. 10, 2025- Global Alzheimer’s Platform Foundation® (GAP) announces the addition of Ichor Research, a leading private a clinical research organization based in Syracuse, New York, to its global network of over 100 best-in-class research sites. Specializing in neurodegenerative clinical trials, […]

GAP Citizen Scientist awards honor individuals’ contributions to research by Andrea Lobo | March 6, 202 A research advocate diagnosed with Parkinson’s disease and a former nurse with Alzheimer’s disease were among recipients of volunteer awards from the Global Alzheimer’s Platform Foundation (GAP).AGAP’s Citizen Scientist Awards acknowledge the contributions of volunteers in clinical trials for neurodegenerative diseases. Each year, GAP’s network of research sites, […]

The free clinical trial at Axiom Brain Health in Tampa works to detect early signs of Alzheimer’s and other cognitive diseases, even years before symptoms appear. Author: Hannah Dineen Published: 4:04 PM EST March 6, 2025 Updated: 8:52 PM EST March 6, 2025 TAMPA, Fla. — It’s estimated nearly 7 million people in the U.S. are living with Alzheimer’s disease. […]

Washington D.C., Feb. 28, 2025 -The Global Alzheimer’s Platform Foundation® (GAP) proudly announced the 2024 National Citizen Scientist Awards® elevated honorees at their 2025 GAP-Net Site Optimization Conference in Miami, Florida. GAP’s Citizen Scientist Awards (CSA) celebrate the contributions of individuals who make a difference by volunteering in clinical trials for neurodegenerative diseases. This year’s […]

Washington D.C., Feb. 18, 2025- The Global Alzheimer’s Platform Foundation ® (GAP) is gravely concerned over news of terminations of key leaders at the National Institute of Health and the Federal Drug Administration along with the firing of thousands of employees from the Department of Health and Human Services over the weekend. John Dwyer, the […]

Washington D.C., Feb. 18, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities […]

Ralph Kern, MD, MHSc, CMO of Cognito Therapeutics, discusses scaling up clinical trials, integrating patient centricity and transitioning from therapeutics to device treatments. February 13, 2025 Tell us about the scientific foundation behind the Spectris ADTM device. Our non-invasive investigational Spectris ADTM device evokes 40 Hz brain gamma oscillations through audiovisual stimulation. It’s delivered in […]

Could a headset with flashing lights and sounds stimulate brain waves and treat Alzheimer’s? Cognito’s Phase 3 trial on such a device is trying to answer that question. Neuropsychologist Dr. Michelle Papka, the trial’s principal investigator and founder of the CRCNJ, explains the science. Researchers and technology companies are investigating whether non-invasive electromagnetic, visual, and […]

The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum of understanding, the consortium, led by scholars from Harvard University, will gain early access to Bio-Hermes-001 data to investigate the potential for […]

January 30, 2025 10:24 PM in News – Local By: Lily Celeste The Rio Grande Valley has one of the highest rates of Alzheimer’s in the country, and a clinic in Rio Grande city is attempting to find out why. Dina Ximenez said she’s been volunteering for three years for Alzheimer’s studies conducted by El Faro Health Clinic […]

Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data  Washington D.C., Jan. 30, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum […]

By Anjelica Rubin – Technology/Tampa Bay Inno reporter, Tampa Bay Business Journal Jan 27, 2025 Updated Jan 28, 2025 5:39pm EST Just over one year after being acquired to help build a clinical research center, Tampa-based Axiom Brain Health celebrated the next chapter in its neurodegenerative research at the launch of its new site on Jan. 23.  The expansion […]

Washington D.C., Jan. 27, 2025– Global Alzheimer’s Platform Foundation® (GAP) applauds the U.S. Food and Drug Administration (FDA)’s approval of IV maintenance dosing for the treatment LEQEMBI®. With this approval, after a patient completes 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of once every four weeks […]

Tampa, Fla. Jan. 24, 2025—Axiom Brain Health (Axiom) and the Global Alzheimer’s Platform Foundation® (GAP) celebrated the next chapter in neurodegenerative research at the launch of the newly renovated site on Thursday, January 23. The expansion of the research facility accommodates the growing need for more research of Alzheimer’s, Multiple Sclerosis, Parkinson’s, and other life-threatening […]

Washington D.C., Jan. 23, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 study. This first-time collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images […]

By Austin Montgomery| December 11, 2024 Global Alzheimer’s Platform Foundation (GAP) has partnered with Eli Lilly and Company (NYSE: LLY) for a study comparing blood tests that could help predict and diagnose Alzheimer’s disease. The Bio-Hermes-002 study looks to increase participation of underrepresented older adults within typical Alzheimer’s clinical research, with at least 25% participation earmarked […]

Some turn to clinical trials to access breakthrough drugs By Cindy Krischer Goodman | cgoodman@sunsentinel.com | South Florida Sun Sentinel UPDATED: December 11, 2024 at 8:00 AM EST The federal Food & Drug Administration has approved two new Alzheimer’s medications that can offer people more time to live normally, but accessing them in Florida is complicated. Hold-ups related to insurance […]

The Global Alzheimer’s Platform Foundation (GAP) is excited to announce its collaboration with Eli Lilly and Company on the transformative Bio-Hermes-002 study. This partnership is poised to broaden the understanding of Alzheimer’s disease by integrating advanced biomarkers that may assist in its early detection and diagnosis. Significance of the Bio-Hermes-002 Study Like its predecessor, Bio-Hermes-001, […]

Citizen Scientists Suzanne and Mike O’Brien of #GAPNet site JEM Research Institute

ViewMind Precision Neurological Assessments ViewMind Digital BiomarkerPublished 7:31 AM EST, December 10, 2024Share To Enhance Alzheimer’s Diagnosis Through Diverse Biomarker Analysis “We expect ViewMind’s promising technology to offer the field alternative methods for detecting and diagnosing Alzheimer’s disease.”— John Dwyer, President of the Global Alzheimer’s Platform Foundation NEW YORK CITY, NY, UNITED STATES, December 10, […]

Washington D.C., Dec. 9, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This collaboration will enrich the unique, observational platform study that compares blood-based and digital biomarkers across a broad range of races and ethnicities that may help predict and diagnose Alzheimer’s […]

Washington D.C., Nov. 26, 2024- The Centers for Medicare & Medicaid Services (CMS) released the Clinical Laboratory Fee Schedule (CLFS) 2025 Final Rate Determinations yesterday, unveiling that clinically critical codes for the reimbursement of Alzheimer neurological biomarker blood tests have been referred to the process known as “gapfill.” Earlier this year, the preliminary recommendation for […]

By ActionNewsJax.com News Staff, November 18, 2024 at 5:32 pm EST Jacksonville Center for Clinical Research just joined the Global Alzheimer’s Platform Foundation’s national network of research centers. According to a news release, the JCCR has conducted more than 1,000 clinical trials over 25 years. Global Alzheimer’s Platform President John Dwyer said the organization wants to […]